EZH2
MOLECULAR TARGETenhancer of zeste 2 polycomb repressive complex 2 subunit
EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) is targeted by 8 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting EZH2
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | tazemetostat | 3.78 | 43 |
| 2 | gsk2816126 | 3.18 | 23 |
| 3 | s adenosylhomocysteine | 3.00 | 19 |
| 4 | cpi 1205 | 1.79 | 5 |
| 5 | myricetin-3-O-galactopyranoside [Supplementary Concept] | 0.69 | 1 |
| 6 | Quercetin | 0.69 | 1 |
| 7 | Biotin | 0.69 | 1 |
| 8 | Sorafenib | 0.69 | 1 |
About EZH2 as a Drug Target
EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 8 compounds with documented EZH2 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
EZH2 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.